Explore

Mayo Clinic Seeks Leading Scientist for Neuroscience Research in Florida

Mayo Clinic Seeks Leading Scientist for Neuroscience Research in Florida

Mayo Clinic's Department of Neuroscience is actively recruiting a distinguished scientist to establish a robust research program focused on neurodegenerative and related diseases at its Florida site in Jacksonville. The ideal candidate, holding a PhD, MD/PhD, or MD, is expected to possess an exceptional track record in innovative scientific discovery with a strong translational component. This includes expertise in biomarker discoveries, novel therapeutic approaches such as RNA and cellular therapies, and the utilization of human data, biospecimens, and model systems to accelerate the development of disease-modifying therapies and cures. The scientist will integrate efforts across various disciplines, including Neuroscience, Neurology, Artificial Intelligence, and Pathology and Laboratory Medicine, to leverage large-scale human datasets and biospecimens. The role emphasizes uncovering key disease mechanisms and driving predictive and therapeutic advancements by combining expertise in human disease biology,...

Plant-Inspired Synthetic Molecules Show Promise Against Alzheimer's Enzyme

Plant-Inspired Synthetic Molecules Show Promise Against Alzheimer's Enzyme

A new comprehensive review published in the Journal of Saudi Chemical Society highlights the potential of synthetic molecules, inspired by plant chemistry, as a promising avenue for Alzheimer's disease treatment. Led by Aruna Ghose and colleagues at Siksha 'O' Anusandhan University in India, the review synthesizes five years of research into synthetic modulators of acetylcholinesterase. This enzyme is crucial because it breaks down acetylcholine, a neurotransmitter vital for memory and attention, and its degeneration is a hallmark of Alzheimer's. Current drugs offer only symptomatic relief by blocking this enzyme, but their effectiveness wanes as cholinergic neurons continue to die. The review argues that acetylcholinesterase is not merely a cleanup enzyme but actively contributes to Alzheimer's pathologies, including accelerating amyloid-beta aggregation and activating tau protein hyperphosphorylation. The research focuses on developing multitarget-directed ligands that not only block the enzyme's active ...

Genetic Discoveries Uncover Potential Protective Genes Against APOE4 Alzheimer's Risk

Genetic Discoveries Uncover Potential Protective Genes Against APOE4 Alzheimer's Risk

New genetic discoveries are enhancing the understanding of neurodegenerative diseases, particularly Alzheimer's. Michael Belloy, an assistant professor at Washington University in St. Louis, analyzed genetic data from nearly 450,000 individuals, focusing on those who carried one or two copies of the APOE4 risk gene but did not develop Alzheimer's. The APOE4 gene significantly increases Alzheimer's risk, by four to twelve-fold. Belloy and his team identified 42 DNA regions, including 29 new ones, linked to APOE4 status that may offer protection against the disease. Many of these protective genes were found to be active in oligodendrocytes, brain cells responsible for forming fatty sheaths around neurons, which are crucial for efficient communication. Specifically, the TNS3 and CISD1 genes were highlighted as potentially important risk modifiers, playing roles in oligodendrocyte maturation, survival, and metabolism. Laura Nisenbaum, chief scientific officer of the Alzheimer’s Drug Discovery Foundation, noted...

German and US scientists win Nobel medicine prize for work on light and brain

German and US scientists win Nobel medicine prize for work on light and brain

By Johan Ahlander, Marie Mannes and Bhanvi Satija STOCKHOLM, Oct 5 (Reuters) - American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel won the 2026 Nobel Prize in Physiology or Medicine on Monday for developing optogenetics, a technique that uses light to control individual nerve cells

New Study Reveals Human Tau Seeds Trigger Disease-Specific Misfolding in Mouse Brains

New Study Reveals Human Tau Seeds Trigger Disease-Specific Misfolding in Mouse Brains

A new study published in Nature has found that human tau seeds from Alzheimer's disease (AD) and corticobasal degeneration (CBD) can trigger disease-specific misfolding of tau proteins in the brains of healthy mice. Researchers injected tiny amounts of human tau seeds from deceased individuals with AD or CBD into mouse brains. High-resolution microscopy revealed that the mice's own tau proteins misfolded into exact 3D structural copies of the original diseased seeds. Although the human seeds vanished within a week, they initiated a chain reaction, causing the mice's tau to continue forming fibers with matching disease-specific folds and accumulate over the subsequent nine to twelve months. Tau is a naturally occurring protein essential for neuron development and communication, but its misfolding and abnormal buildup are hallmarks of neurodegenerative diseases like Alzheimer's. This research provides structural evidence supporting the prion hypothesis, which suggests that misfolded proteins spread by forcin...

AI-Powered Causal Discovery Explores Vasospasm in ICU Patients

AI-Powered Causal Discovery Explores Vasospasm in ICU Patients

Researchers at Universiteit Gent are utilizing Artificial Intelligence (AI) to investigate the causes of vasospasm in Intensive Care Unit (ICICU) patients following a brain hemorrhage. This condition, where blood vessels in the brain suddenly narrow, can lead to oxygen deprivation, brain damage, or death. Despite being known for decades, the exact mechanisms behind vasospasm remain poorly understood. The study employs AI to analyze vast amounts of patient data, including the large public dataset MIMIC-IV, which contains medical records from thousands of ICU patients. A key challenge identified was the difficulty in accurately identifying vasospasm cases from structured patient data, as official diagnoses were often missing, while mentions were more frequent in doctors' and radiologists' reports. To address this, a system was developed that combines structured data with text from medical records, using a language model similar to ChatGPT to process hundreds of discharge letters and radiological reports. Thi...

AI Discovers Novel Alzheimer's Drug Candidate Targeting Galectin-3

AI Discovers Novel Alzheimer's Drug Candidate Targeting Galectin-3

A deep-learning platform named Llama-Gram has identified a new drug candidate, FJMU1887, for Alzheimer's disease. This AI-driven discovery process involved screening approximately 2.58 million protein-ligand interactions, incorporating protein structural representations from ESMFold, graph-based representations of chemical compounds, and deep-learning predictions of protein-ligand interactions. The system prioritized candidates based on binding-probability scoring and uncertainty estimation, leading to the selection of FJMU1887. Subsequent laboratory validation confirmed that FJMU1887 directly binds to Galectin-3 (Gal-3) and disrupts its interaction with TREM2, a receptor involved in microglial regulation. In BV-2 microglial cells, FJMU1887 reduced inflammatory responses, including the inhibition of TNF-α, without significant cytotoxicity. The compound also demonstrated the ability to cross the blood-brain barrier, a critical challenge for Alzheimer's drugs, and was detected in the plasma and brain tissue ...

High-Fat Diet Linked to Brain Damage in MS Through Gut Bacteria Alterations, Mouse Study Suggests

High-Fat Diet Linked to Brain Damage in MS Through Gut Bacteria Alterations, Mouse Study Suggests

A study conducted in mice suggests that a high-fat diet may exacerbate disability in individuals with multiple sclerosis (MS) by altering gut bacteria composition. This alteration leads to changes in the number of immune cells entering the brain. Researchers found that a high-fat diet increased brain glutamate levels in mice, a neurotransmitter that, when in excess, can cause damage to nerve cell connections. The study also observed a reduction in beneficial Lactobacillus bacteria in the gut of mice on a high-fat diet. Administering probiotics containing Lactobacillus and other immune-regulating bacteria was shown to reduce the impact of the high-fat diet on brain glutamate levels, suggesting the gut microbiota mediates these effects. Medications blocking immune cell movement into the brain also mitigated the negative effects.

Gut Bacteria Compound Linked to Increased Alzheimer's Risk and Cognitive Decline

Gut Bacteria Compound Linked to Increased Alzheimer's Risk and Cognitive Decline

New research indicates that a molecule produced by gut bacteria, imidazole propionate (ImP), may elevate the risk of Alzheimer's disease and accelerate cognitive decline in individuals with dementia. The study, led by University of Wisconsin-Madison professors Barbara Bendlin and Federico Rey, found that ImP can enter the bloodstream and reach the brain, where it contributes to the accumulation of abnormal beta amyloid and tau proteins, hallmarks of Alzheimer's. Participants in the Wisconsin Registry for Alzheimer's Prevention with higher blood ImP concentrations showed more biological markers associated with abnormal proteins and impaired neuron function, as well as faster cognitive decline. A genetic variation, present in about 43% of the study population, was also linked to substantially higher ImP levels, potentially by affecting kidney removal of the compound.

Alzheimer's Biology Exacerbates Long-Term Brain Damage After Traumatic Brain Injury, Study Finds

Alzheimer's Biology Exacerbates Long-Term Brain Damage After Traumatic Brain Injury, Study Finds

New research from the University of Miami Miller School of Medicine indicates that Alzheimer's disease-related biology intensifies chronic inflammation and brain damage following traumatic brain injury (TBI). The study, led by investigators at The Miami Project to Cure Paralysis, found that individuals with Alzheimer's-associated biological changes experienced more severe chronic inflammation, greater brain tissue loss, and higher levels of neurodegeneration markers after TBI. Specifically, if a traumatic brain injury occurs in someone with Alzheimer's disease, the inflammatory response persists chronically instead of subsiding, unlike in individuals without Alzheimer's. This persistent inflammation is linked to increased loss of brain tissue in regions vital for memory and cognition, such as the cortex and hippocampus. The research also identified elevated levels of glial fibrillary acidic protein (GFAP) and neurofilament light (NfL), markers associated with chronic neuroinflammation and axonal damage, re...

Anti-Inflammatory Diets and Key Nutrients Crucial for Traumatic Brain Injury Recovery

Anti-Inflammatory Diets and Key Nutrients Crucial for Traumatic Brain Injury Recovery

Optimal nutrition, particularly anti-inflammatory dietary patterns, is foundational for recovery from mild traumatic brain injury (mTBI). Following an mTBI, the brain undergoes a metabolic crisis characterized by neuroinflammation, oxidative stress, and increased energy demand. Dietary patterns like the Mediterranean diet and the neurologically targeted MIND diet are consistently associated with reduced systemic inflammation, improved cognitive aging outcomes, and better neurological function. The MIND diet specifically emphasizes brain-protective foods such as leafy green vegetables and berries while limiting red meat, butter, cheese, pastries, and fried foods that promote neuroinflammation. Key nutrients supporting mTBI recovery include Omega-3 fatty acids (DHA and EPA) for resolving neuroinflammation and protecting neurons, antioxidants and polyphenols (from blueberries, dark chocolate, green tea, turmeric) to neutralize reactive oxygen species, and adequate protein and amino acids for neurotransmitter ...

Avner Schlessinger Appointed Chair of UNC Department of Pharmacology

Avner Schlessinger Appointed Chair of UNC Department of Pharmacology

Avner Schlessinger, PhD, has been named the new chair of the UNC Department of Pharmacology at the University of North Carolina at Chapel Hill. Dr. Schlessinger is slated to begin his tenure in February 2027. He will succeed Henrik Dohlman, PhD, who will step down from the chair position in February but will remain a faculty member within the department. Dr. Schlessinger is currently the director of the AI Small Molecule Drug Discovery Center and the Dr. Amy and James Elster Professor of Molecular Biology and a professor of pharmacological sciences at the Icahn School of Medicine at Mount Sinai. His research focuses on integrating computational chemistry, artificial intelligence, structural biology, and experimental pharmacology to improve and automate the structure-based drug discovery process. He holds a B.Sc. in chemistry and biology from Tel Aviv University and a PhD in biochemistry and molecular biophysics from Columbia University.